{
  "protocol": {
    "name": "FOLFOX Chemotherapy for Colorectal Cancer (Adjuvant)",
    "version": "1.0",
    "therapy_type": "chemotherapy",
    "condition_treated": "Stage III Colorectal Cancer (Adjuvant Treatment)",
    "evidence_level": "fda_approved",
    "overview": "Modified FOLFOX6 regimen for adjuvant treatment of stage III colon cancer following surgical resection. This protocol combines oxaliplatin, leucovorin, and 5-fluorouracil (5-FU) administered every 2 weeks for 12 cycles (24 weeks total). Based on MOSAIC trial and NCCN guidelines.",
    "duration_weeks": 24,
    "total_sessions": 36,
    "evidence_sources": [
      "Andre T, et al. N Engl J Med. 2004;350(23):2343-2351 (MOSAIC trial)",
      "NCCN Clinical Practice Guidelines in Oncology: Colon Cancer v2.2024",
      "FDA approval for oxaliplatin in combination with 5-FU/LV"
    ]
  },
  "steps": [
    {
      "sequence_order": 1,
      "step_type": "screening",
      "title": "Oncology Consultation & Treatment Planning",
      "description": "Comprehensive oncology consultation to review pathology, staging, discuss treatment goals, risks/benefits, and obtain informed consent for adjuvant chemotherapy.",
      "duration_minutes": 90,
      "required_roles": ["medical_oncologist", "oncology_nurse"],
      "documentation_requirements": {
        "staging": "Pathologic stage (TNM), number of nodes examined and positive",
        "surgery": "Type and date of resection, margin status, complications",
        "performance_status": "ECOG performance status (0-2 required for treatment)",
        "comorbidities": "Cardiac, renal, hepatic, neurologic history",
        "goals_of_care": "Curative intent adjuvant therapy discussion"
      },
      "informed_consent_topics": [
        "Rationale for adjuvant chemotherapy (reduction in recurrence risk)",
        "Expected treatment schedule (12 cycles, 24 weeks)",
        "Common side effects (neuropathy, nausea, diarrhea, fatigue, cytopenias)",
        "Serious risks (neutropenic fever, severe neuropathy, allergic reactions)",
        "Fertility impact and contraception requirements",
        "Alternative treatment options",
        "Right to refuse or discontinue treatment"
      ]
    },
    {
      "sequence_order": 2,
      "step_type": "screening",
      "title": "Pre-Treatment Assessment & Baseline Labs",
      "description": "Comprehensive baseline assessment including laboratory tests, imaging, and functional assessments required before chemotherapy initiation.",
      "duration_minutes": 60,
      "required_roles": ["oncology_nurse", "phlebotomist"],
      "lab_tests_required": [
        "Complete Blood Count with Differential (CBC)",
        "Comprehensive Metabolic Panel (CMP) including creatinine, liver enzymes",
        "Magnesium, calcium, phosphorus",
        "Carcinoembryonic Antigen (CEA) baseline",
        "Pregnancy test (if applicable)",
        "Blood type and screen (if port placement planned)"
      ],
      "imaging_required": [
        "CT chest/abdomen/pelvis (baseline restaging post-surgery)"
      ],
      "functional_assessments": [
        {
          "assessment": "ECOG Performance Status",
          "requirement": "Must be 0-2 to proceed with treatment"
        },
        {
          "assessment": "Neurologic Exam",
          "purpose": "Baseline neuropathy assessment (CTCAE grading)",
          "required": "Document any pre-existing neuropathy"
        },
        {
          "assessment": "Nutritional Assessment",
          "purpose": "Assess for malnutrition, plan supportive care"
        }
      ],
      "vitals_monitoring": {
        "required": ["blood_pressure", "heart_rate", "temperature", "weight", "height", "bsa"]
      },
      "minimum_lab_requirements": {
        "anc": "> 1500/μL",
        "platelets": "> 100,000/μL",
        "creatinine_clearance": "> 30 mL/min (for oxaliplatin dosing)",
        "total_bilirubin": "< 2x ULN",
        "ast_alt": "< 3x ULN"
      }
    },
    {
      "sequence_order": 3,
      "step_type": "preparation",
      "title": "Vascular Access Placement (Optional)",
      "description": "Placement of central venous catheter (port-a-cath or PICC) for chemotherapy administration and labs if needed. Not required but often preferred for patient comfort.",
      "duration_minutes": 60,
      "required_roles": ["interventional_radiologist", "surgeon"],
      "options": [
        {
          "device": "Implanted Port (Port-a-Cath)",
          "pros": ["Most convenient for long-term use", "Preserved peripheral veins", "Better quality of life"],
          "cons": ["Surgical procedure", "Infection risk", "Cost"],
          "preferred": true
        },
        {
          "device": "PICC Line",
          "pros": ["Less invasive", "Can be placed at bedside"],
          "cons": ["External catheter", "Activity restrictions", "Higher thrombosis risk"],
          "preferred": false
        },
        {
          "device": "Peripheral IV",
          "pros": ["No procedure needed"],
          "cons": ["Vein irritation", "Difficult 5-FU pump connection", "Repeated sticks"],
          "preferred": false
        }
      ],
      "post_placement_requirements": [
        "Chest X-ray to confirm position (for PICC/port)",
        "Patient education on care and flushing",
        "Emergency instructions for complications"
      ]
    },
    {
      "sequence_order": 4,
      "step_type": "decision_point",
      "title": "Chemotherapy Dose Calculation & Regimen Confirmation",
      "description": "Calculate individualized chemotherapy doses based on body surface area (BSA) and renal function. Confirm FOLFOX6 regimen dosing.",
      "duration_minutes": 20,
      "required_roles": ["medical_oncologist", "oncology_pharmacist"],
      "evaluation_rules": {
        "type": "dose_calculation",
        "bsa_calculation": "Mosteller formula: sqrt((height_cm x weight_kg) / 3600)",
        "dose_capping": {
          "maximum_bsa": 2.2,
          "rationale": "Reduce toxicity in very large patients without compromising efficacy"
        },
        "renal_dose_adjustment": {
          "oxaliplatin": [
            {
              "creatinine_clearance": "> 50 mL/min",
              "dose_adjustment": "No adjustment needed"
            },
            {
              "creatinine_clearance": "30-50 mL/min",
              "dose_adjustment": "Reduce oxaliplatin to 65 mg/m²"
            },
            {
              "creatinine_clearance": "< 30 mL/min",
              "dose_adjustment": "Consider alternative regimen (CAPOX or 5-FU/LV alone)"
            }
          ]
        },
        "standard_folfox6_regimen": {
          "cycle_length": "14 days (every 2 weeks)",
          "total_cycles": 12,
          "day_1_drugs": [
            {
              "drug": "Oxaliplatin",
              "dose": "85 mg/m²",
              "route": "IV infusion over 2 hours",
              "sequence": 1
            },
            {
              "drug": "Leucovorin",
              "dose": "400 mg/m²",
              "route": "IV infusion over 2 hours (concurrent with oxaliplatin)",
              "sequence": 1
            },
            {
              "drug": "5-Fluorouracil",
              "dose": "400 mg/m²",
              "route": "IV bolus",
              "sequence": 2,
              "timing": "After leucovorin/oxaliplatin"
            },
            {
              "drug": "5-Fluorouracil",
              "dose": "2400 mg/m²",
              "route": "Continuous IV infusion over 46 hours via pump",
              "sequence": 3,
              "timing": "Immediately after bolus"
            }
          ],
          "day_3_intervention": [
            {
              "intervention": "5-FU pump disconnect",
              "timing": "Approximately 46-48 hours after pump connection"
            }
          ]
        }
      },
      "branch_outcomes": [
        {
          "outcome_id": "standard_dosing",
          "description": "Normal renal function, standard FOLFOX6 doses calculated",
          "next_step": 5
        },
        {
          "outcome_id": "renal_adjusted_dosing",
          "description": "Renal impairment, oxaliplatin dose reduced",
          "next_step": 5
        }
      ]
    },
    {
      "sequence_order": 5,
      "step_type": "preparation",
      "title": "Pre-Chemotherapy Patient Education",
      "description": "Comprehensive education session covering chemotherapy administration, expected side effects, self-care strategies, and emergency contact information.",
      "duration_minutes": 45,
      "required_roles": ["oncology_nurse", "oncology_pharmacist"],
      "education_topics": [
        {
          "topic": "Treatment Schedule",
          "content": "12 cycles every 2 weeks (total 24 weeks), Day 1 infusion (~6 hours), Day 3 pump disconnect, labs before each cycle"
        },
        {
          "topic": "Common Side Effects",
          "content": [
            "Neuropathy (cold sensitivity, numbness/tingling) - cumulative with oxaliplatin",
            "Nausea/vomiting - usually controlled with medications",
            "Diarrhea - take anti-diarrheal as prescribed",
            "Fatigue - pace yourself, rest as needed",
            "Mouth sores - good oral hygiene, avoid spicy/acidic foods",
            "Hair thinning (not complete baldness typically)"
          ]
        },
        {
          "topic": "Neutropenia Precautions",
          "content": "Avoid crowds, wash hands frequently, report fever > 100.4°F immediately"
        },
        {
          "topic": "Cold Sensitivity (Oxaliplatin)",
          "content": "Avoid cold drinks/foods for 3-5 days after treatment, wear gloves for cold items, no ice"
        },
        {
          "topic": "5-FU Pump Care",
          "content": "Wear pump in provided pouch, avoid getting wet, return if alarm sounds or stops working"
        },
        {
          "topic": "Supportive Medications",
          "content": "Anti-nausea, anti-diarrheal, growth factors if needed - when and how to take"
        },
        {
          "topic": "Emergency Symptoms",
          "content": [
            "Fever ≥ 100.4°F (neutropenic fever emergency)",
            "Severe diarrhea (> 6 stools/day or bloody)",
            "Difficulty breathing or chest pain",
            "Severe allergic reaction (rash, swelling, wheezing)",
            "Uncontrolled nausea/vomiting",
            "Signs of blood clots (leg pain, swelling, redness)"
          ]
        }
      ],
      "handouts_provided": [
        "FOLFOX patient guide",
        "Neuropathy management tips",
        "Neutropenia precautions",
        "Diet recommendations during chemotherapy",
        "24/7 oncology on-call number"
      ]
    },
    {
      "sequence_order": 6,
      "step_type": "dosing",
      "title": "Cycle 1, Day 1 - Chemotherapy Infusion",
      "description": "First chemotherapy treatment with FOLFOX regimen. Includes pre-medications, oxaliplatin, leucovorin, 5-FU bolus, and connection of 5-FU continuous infusion pump.",
      "duration_minutes": 360,
      "required_roles": ["oncology_nurse", "medical_oncologist", "oncology_pharmacist"],
      "pre_medications": [
        {
          "medication": "Dexamethasone",
          "dose": "12 mg IV",
          "timing": "30 minutes before chemotherapy"
        },
        {
          "medication": "Ondansetron or Palonosetron",
          "dose": "Ondansetron 16-24 mg IV or Palonosetron 0.25 mg IV",
          "timing": "30 minutes before chemotherapy"
        },
        {
          "medication": "Diphenhydramine (optional)",
          "dose": "25-50 mg IV",
          "timing": "If history of oxaliplatin reactions"
        }
      ],
      "infusion_sequence": [
        {
          "step": 1,
          "medication": "Oxaliplatin + Leucovorin",
          "dose": "85 mg/m² oxaliplatin + 400 mg/m² leucovorin",
          "route": "Concurrent IV infusion via Y-connector",
          "duration": "2 hours",
          "special_instructions": "Do NOT use ice for extravasation. Oxaliplatin in D5W (never saline)"
        },
        {
          "step": 2,
          "medication": "5-Fluorouracil bolus",
          "dose": "400 mg/m²",
          "route": "IV push",
          "duration": "5-10 minutes",
          "timing": "After oxaliplatin/leucovorin completion"
        },
        {
          "step": 3,
          "medication": "5-Fluorouracil continuous infusion",
          "dose": "2400 mg/m²",
          "route": "Continuous IV infusion via portable pump",
          "duration": "46 hours",
          "timing": "Immediately after bolus, patient goes home with pump"
        }
      ],
      "vitals_monitoring": {
        "frequency": "Every 30 minutes during infusion",
        "parameters": ["blood_pressure", "heart_rate", "respiratory_rate", "temperature", "oxygen_saturation"],
        "infusion_reaction_watch": "Especially during oxaliplatin - monitor for bronchospasm, rash, hypotension"
      },
      "nursing_assessments": [
        "IV site patency and phlebitis monitoring",
        "Nausea/vomiting assessment",
        "Immediate hypersensitivity reaction monitoring",
        "Patient teaching reinforcement",
        "5-FU pump function verification before discharge"
      ],
      "discharge_criteria": [
        "Stable vital signs",
        "No severe infusion reactions",
        "5-FU pump functioning properly",
        "Patient/caregiver understands pump care and emergency instructions",
        "Prescriptions provided for home anti-emetics and anti-diarrheals"
      ],
      "safety_checks": [
        {
          "check": "Chemotherapy verification",
          "requirement": "Two RN verification of patient identity, drug, dose, route per institutional policy"
        },
        {
          "check": "Extravasation kit",
          "requirement": "Available at bedside - note: NO ice for oxaliplatin extravasation"
        },
        {
          "check": "Emergency medications",
          "requirement": "Epinephrine, diphenhydramine, hydrocortisone immediately available"
        }
      ]
    },
    {
      "sequence_order": 7,
      "step_type": "followup",
      "title": "Cycle 1, Day 3 - 5-FU Pump Disconnect",
      "description": "Patient returns to clinic for removal of 5-FU continuous infusion pump, assessment of acute toxicities, and supportive care.",
      "duration_minutes": 20,
      "required_roles": ["oncology_nurse"],
      "assessments": [
        "Pump completion verification (should be empty or near-empty)",
        "IV site assessment (if peripheral) or port access site",
        "Nausea/vomiting control",
        "Diarrhea assessment",
        "Mucositis screening",
        "Hand-foot syndrome (palmar-plantar erythrodysesthesia) check",
        "Cold sensitivity symptoms from oxaliplatin"
      ],
      "interventions": [
        "Remove and dispose of 5-FU pump per chemotherapy waste protocol",
        "Flush port or remove peripheral IV",
        "Medication adjustments if needed (anti-emetics, anti-diarrheals)",
        "Patient education reinforcement on delayed side effects"
      ],
      "symptom_management": {
        "nausea": "Prescribe additional anti-emetics if breakthrough nausea",
        "diarrhea": "Loperamide as needed, hydration counseling",
        "cold_sensitivity": "Reassure temporary, avoid cold for 3-5 days"
      }
    },
    {
      "sequence_order": 8,
      "step_type": "followup",
      "title": "Mid-Cycle Phone Follow-up (Day 7-10)",
      "description": "Nurse-initiated phone call to assess delayed side effects, medication adherence, and supportive care needs between cycles.",
      "duration_minutes": 15,
      "required_roles": ["oncology_nurse"],
      "assessment_checklist": [
        "Fatigue level (0-10 scale)",
        "Nausea/vomiting (frequency and severity)",
        "Diarrhea (number of stools per day, hydration status)",
        "Neuropathy symptoms (cold sensitivity resolved? any numbness/tingling?)",
        "Mouth sores or difficulty swallowing",
        "Fever or signs of infection",
        "Medication adherence and any issues with prescriptions",
        "Questions or concerns for next treatment"
      ],
      "red_flag_symptoms_requiring_immediate_escalation": [
        "Fever ≥ 100.4°F",
        "Severe diarrhea (> 6 stools/day or bloody stools)",
        "Intractable nausea/vomiting",
        "Signs of dehydration",
        "Chest pain or dyspnea",
        "Severe abdominal pain"
      ],
      "documentation": "Document call in EMR, escalate concerns to oncologist, provide reassurance and supportive care guidance"
    },
    {
      "sequence_order": 9,
      "step_type": "decision_point",
      "title": "Pre-Cycle Labs & Treatment Decision (Day 14)",
      "description": "Laboratory assessment before each cycle to determine fitness to proceed with chemotherapy, need for dose adjustments, or treatment delays.",
      "duration_minutes": 30,
      "required_roles": ["medical_oncologist", "oncology_nurse"],
      "lab_tests_required": [
        "Complete Blood Count with Differential (CBC)",
        "Comprehensive Metabolic Panel (CMP)",
        "Magnesium level"
      ],
      "clinical_assessment": [
        "ECOG performance status",
        "Neuropathy assessment (CTCAE grade)",
        "Mucositis grade",
        "Diarrhea grade",
        "Hand-foot syndrome grade",
        "Overall toxicity review"
      ],
      "evaluation_rules": {
        "type": "treatment_decision",
        "proceed_criteria": {
          "anc": "> 1500/μL",
          "platelets": "> 75,000/μL",
          "creatinine": "< 1.5x baseline or CrCl > 30 mL/min",
          "total_bilirubin": "< 2x ULN",
          "neuropathy": "≤ Grade 2",
          "diarrhea": "Resolved to ≤ Grade 1",
          "mucositis": "Resolved to ≤ Grade 1"
        },
        "delay_criteria": [
          {
            "condition": "anc_low",
            "threshold": "ANC 1000-1500/μL",
            "action": "Delay 1 week, recheck labs"
          },
          {
            "condition": "platelets_low",
            "threshold": "Platelets 50,000-75,000/μL",
            "action": "Delay 1 week, recheck labs"
          },
          {
            "condition": "neuropathy_grade_3",
            "action": "Hold oxaliplatin until ≤ Grade 1, consider dose reduction"
          },
          {
            "condition": "severe_diarrhea_grade_3_4",
            "action": "Delay until resolved to Grade 1, reduce 5-FU dose by 20%"
          }
        ],
        "dose_reduction_criteria": [
          {
            "toxicity": "Neutropenic fever or Grade 4 neutropenia",
            "dose_modification": "Reduce 5-FU bolus and infusion by 20%"
          },
          {
            "toxicity": "Grade 3 neuropathy",
            "dose_modification": "Reduce oxaliplatin from 85 to 65 mg/m²"
          },
          {
            "toxicity": "Persistent Grade 2 neuropathy",
            "dose_modification": "Consider reducing oxaliplatin from 85 to 75 mg/m² after cycle 6-8"
          },
          {
            "toxicity": "Grade 3-4 diarrhea",
            "dose_modification": "Reduce 5-FU by 20%"
          },
          {
            "toxicity": "Grade 3-4 mucositis",
            "dose_modification": "Reduce 5-FU by 20%"
          }
        ],
        "discontinuation_criteria": [
          {
            "condition": "Grade 4 neuropathy or persistent Grade 3",
            "action": "Discontinue oxaliplatin permanently, continue 5-FU/LV if appropriate"
          },
          {
            "condition": "Severe allergic reaction to oxaliplatin",
            "action": "Discontinue oxaliplatin, consider alternative regimen"
          },
          {
            "condition": "Disease progression",
            "action": "Discontinue protocol, reassess treatment plan"
          },
          {
            "condition": "Patient decline ECOG ≥ 3",
            "action": "Consider treatment discontinuation or palliative care"
          }
        ]
      },
      "branch_outcomes": [
        {
          "outcome_id": "proceed_standard_dose",
          "description": "Labs adequate, no significant toxicities, proceed with standard doses",
          "next_step": 10
        },
        {
          "outcome_id": "proceed_reduced_dose",
          "description": "Prior toxicities require dose reduction, proceed with modified doses",
          "next_step": 10
        },
        {
          "outcome_id": "delay_one_week",
          "description": "Cytopenias or toxicities not resolved, delay treatment 1 week",
          "next_step": 9
        },
        {
          "outcome_id": "modify_regimen",
          "description": "Severe toxicity, modify regimen (e.g., discontinue oxaliplatin, continue 5-FU)",
          "next_step": "modified_protocol"
        },
        {
          "outcome_id": "discontinue_treatment",
          "description": "Unacceptable toxicity or progression, stop chemotherapy",
          "next_step": "exit_protocol"
        }
      ]
    },
    {
      "sequence_order": 10,
      "step_type": "dosing",
      "title": "Subsequent Cycles (Cycles 2-12)",
      "description": "Repeat cycles of FOLFOX chemotherapy following same sequence as Cycle 1, with dose adjustments as determined by toxicity assessments.",
      "duration_minutes": 360,
      "required_roles": ["oncology_nurse", "medical_oncologist"],
      "cycle_components": "Repeat steps 6-9 for each cycle with toxicity-driven modifications",
      "cumulative_toxicity_monitoring": {
        "neuropathy": {
          "concern": "Cumulative with oxaliplatin, often worsens after cycles 8-10",
          "monitoring": "Assess grade at each visit, patient-reported numbness/tingling diary",
          "management": "Dose reduction or discontinuation based on grade and impact on function"
        },
        "fatigue": {
          "concern": "Cumulative fatigue increases over treatment course",
          "monitoring": "Fatigue scale at each visit",
          "management": "Activity balance, nutritional support, rule out anemia"
        },
        "cytopenias": {
          "concern": "Bone marrow reserve may diminish over time",
          "monitoring": "CBC before each cycle",
          "management": "Dose reductions or G-CSF support if recurrent neutropenia"
        }
      },
      "special_cycle_considerations": {
        "cycle_6": "Mid-treatment assessment, consider imaging if symptoms suggest progression",
        "cycle_9_10": "Neuropathy often peaks, many patients require oxaliplatin dose reduction or early discontinuation",
        "cycle_12": "Final cycle - schedule restaging scans and survivorship planning"
      }
    },
    {
      "sequence_order": 11,
      "step_type": "decision_point",
      "title": "Restaging Imaging & Response Assessment",
      "description": "CT scans performed after cycles 4, 8, and 12 to assess for disease recurrence (though rare in adjuvant setting) and post-treatment surveillance planning.",
      "duration_minutes": 30,
      "required_roles": ["medical_oncologist", "radiologist"],
      "imaging_schedule": [
        {
          "timing": "After Cycle 4 (Week 8)",
          "scans": "CT chest/abdomen/pelvis",
          "purpose": "Early assessment, rule out progression (rare but important to catch early)"
        },
        {
          "timing": "After Cycle 8 (Week 16)",
          "scans": "CT chest/abdomen/pelvis",
          "purpose": "Mid-treatment assessment"
        },
        {
          "timing": "After Cycle 12 (Week 24) - End of Treatment",
          "scans": "CT chest/abdomen/pelvis",
          "purpose": "Establish new baseline for surveillance"
        }
      ],
      "evaluation_rules": {
        "type": "response_assessment",
        "outcomes": [
          {
            "finding": "No evidence of disease (NED)",
            "action": "Continue planned treatment to completion, proceed to survivorship care",
            "expected": "Most common in adjuvant setting"
          },
          {
            "finding": "New metastatic disease detected",
            "action": "Stop adjuvant protocol, discuss metastatic treatment options",
            "next_step": "Palliative chemotherapy protocol"
          },
          {
            "finding": "Local recurrence",
            "action": "Multidisciplinary tumor board, consider surgery/radiation +/- chemotherapy change"
          }
        ]
      },
      "additional_monitoring": {
        "cea_levels": "Check CEA with each restaging scan, rising CEA may indicate recurrence even if scans negative"
      },
      "branch_outcomes": [
        {
          "outcome_id": "ned_continue_treatment",
          "description": "No recurrence, continue adjuvant chemotherapy as planned",
          "next_step": 10
        },
        {
          "outcome_id": "recurrence_detected",
          "description": "Disease recurrence identified",
          "next_step": "mtb_discussion"
        }
      ]
    },
    {
      "sequence_order": 12,
      "step_type": "integration",
      "title": "Treatment Completion & Survivorship Planning",
      "description": "Final visit after completing 12 cycles of FOLFOX. Review treatment summary, discuss surveillance plan, address long-term side effects, and transition to survivorship care.",
      "duration_minutes": 60,
      "required_roles": ["medical_oncologist", "oncology_nurse", "survivorship_navigator"],
      "completion_assessments": [
        "Final ECOG performance status",
        "Residual neuropathy grade (often persists for months after oxaliplatin completion)",
        "Fatigue assessment",
        "Nutritional status",
        "Psychosocial adjustment",
        "Quality of life assessment"
      ],
      "survivorship_care_plan_components": [
        {
          "topic": "Treatment Summary",
          "content": "Diagnosis, stage, surgery date, chemotherapy regimen and doses, toxicities experienced, final scans"
        },
        {
          "topic": "Surveillance Schedule",
          "content": [
            "History & Physical: Every 3-6 months for 2 years, then every 6 months for years 3-5, then annually",
            "CEA: Every 3-6 months for 2 years (if elevated at diagnosis)",
            "CT chest/abdomen/pelvis: Annually for 3-5 years",
            "Colonoscopy: 1 year after surgery, then per guidelines based on findings"
          ]
        },
        {
          "topic": "Long-term Side Effects",
          "content": [
            "Neuropathy: May persist for 6-12 months or longer; refer to neurology if severe",
            "Fatigue: Gradual improvement expected over 6-12 months",
            "Cognitive changes: 'Chemo brain' may occur, usually improves with time",
            "Fertility: May be impaired; refer to reproductive endocrinology if pregnancy desired",
            "Secondary malignancies: Small increased risk; maintain cancer screening"
          ]
        },
        {
          "topic": "Healthy Lifestyle",
          "content": [
            "Diet: Balanced diet, maintain healthy weight",
            "Exercise: Goal of 150 minutes moderate activity per week",
            "Smoking cessation: Critical for reducing recurrence risk",
            "Alcohol: Limit intake",
            "Sun protection"
          ]
        },
        {
          "topic": "Psychosocial Support",
          "content": [
            "Cancer survivorship support groups",
            "Individual counseling if needed for anxiety/depression",
            "Financial counseling for treatment costs",
            "Return to work planning"
          ]
        },
        {
          "topic": "Warning Signs",
          "content": "Symptoms that should prompt immediate evaluation: abdominal pain, rectal bleeding, unexplained weight loss, persistent cough, bone pain"
        }
      ],
      "referrals": [
        "Primary care physician (send survivorship care plan)",
        "Neurology (if Grade 2+ neuropathy persists)",
        "Physical therapy (if significant functional impairment)",
        "Nutrition services",
        "Social work/survivorship navigator"
      ],
      "port_removal": {
        "timing": "Can remove 4-8 weeks after final treatment if no longer needed",
        "discussion": "Discuss pros/cons of keeping vs. removing with patient"
      }
    }
  ],
  "supportive_care_throughout_treatment": {
    "nausea_vomiting_prophylaxis": {
      "acute": [
        "Dexamethasone 12 mg IV day 1",
        "Palonosetron 0.25 mg IV or ondansetron 16-24 mg IV day 1",
        "Consider NK-1 antagonist (aprepitant) for high-risk patients"
      ],
      "delayed": [
        "Dexamethasone 8 mg PO days 2-3",
        "Metoclopramide or prochlorperazine as needed",
        "Ondansetron 8 mg PO q8h as needed days 2-5"
      ],
      "breakthrough": [
        "Olanzapine 5-10 mg PO daily (very effective for refractory nausea)",
        "Lorazepam for anticipatory nausea"
      ]
    },
    "diarrhea_management": {
      "prevention": "Loperamide 2 mg after each loose stool, max 16 mg/day",
      "severe_diarrhea": "Hold chemotherapy, hydration (IV if needed), consider hospitalization for Grade 3-4"
    },
    "neuropathy_management": {
      "cold_avoidance": "Critical for 3-5 days post-oxaliplatin",
      "pharmacologic": "Duloxetine 30-60 mg daily (evidence-based for chemotherapy-induced neuropathy)",
      "non_pharmacologic": "Occupational therapy, hand/foot warming, compression gloves"
    },
    "neutropenia_management": {
      "prophylactic_gcsf": "Generally not needed for FOLFOX, but consider if recurrent neutropenia or neutropenic fever",
      "dose_dense_option": "Pegfilgrastim if dose-dense schedule"
    },
    "mucositis_prevention": {
      "oral_cryotherapy": "Ice chips during 5-FU bolus (may reduce mucositis)",
      "oral_care": "Gentle brushing, alcohol-free mouthwash, salt/soda rinses"
    },
    "hand_foot_syndrome": {
      "prevention": "Moisturize hands/feet, avoid heat, wear comfortable shoes",
      "treatment": "Dose reduction of 5-FU if Grade 2-3"
    }
  },
  "safety_monitoring": {
    "absolute_contraindications": [
      "Pregnancy or breastfeeding",
      "Known DPD deficiency (5-FU metabolism)",
      "Severe bone marrow suppression",
      "Severe hepatic or renal impairment",
      "Active uncontrolled infection",
      "ECOG performance status ≥ 3"
    ],
    "serious_adverse_events": [
      {
        "event": "Neutropenic Fever",
        "definition": "ANC < 500/μL + fever ≥ 100.4°F",
        "management": "Emergency! Immediate hospitalization, broad-spectrum antibiotics, G-CSF",
        "future_prevention": "Dose reduction or G-CSF prophylaxis for subsequent cycles"
      },
      {
        "event": "Oxaliplatin Anaphylaxis",
        "incidence": "Rare but can occur, more common with cumulative cycles",
        "management": "Stop infusion, epinephrine, steroids, antihistamines",
        "future_prevention": "Discontinue oxaliplatin permanently"
      },
      {
        "event": "Severe Diarrhea (Grade 3-4)",
        "management": "Hospitalization for IV hydration, hold chemotherapy, dose reduction when resume",
        "complications": "Dehydration, electrolyte abnormalities, renal failure"
      },
      {
        "event": "Thromboembolic Events",
        "risk": "Cancer patients have increased VTE risk",
        "management": "Anticoagulation, consider holding chemotherapy if life-threatening PE",
        "prevention": "Early mobilization, consider prophylaxis in high-risk patients"
      },
      {
        "event": "Hand-Foot Syndrome (Grade 3)",
        "management": "Hold 5-FU, topical steroids, dose reduction when resume"
      }
    ]
  },
  "protocol_modifications_special_populations": {
    "elderly_patients_age_75_plus": {
      "considerations": [
        "Increased toxicity risk, especially neuropathy and cytopenias",
        "Comprehensive geriatric assessment recommended",
        "Consider dose reduction (80% starting dose) or alternative regimen (CAPOX, 5-FU/LV alone)",
        "Enhanced supportive care and monitoring"
      ]
    },
    "renal_impairment": {
      "mild_moderate": "Reduce oxaliplatin dose as per protocol",
      "severe": "Consider alternative regimen without oxaliplatin or close nephrology collaboration"
    },
    "hepatic_impairment": {
      "mild": "Usually tolerated, close monitoring",
      "moderate_severe": "5-FU dose reduction, consider alternative agents"
    }
  },
  "quality_metrics": {
    "completion_rate": "Goal > 70% of patients complete 12 cycles",
    "dose_intensity": "Goal > 85% relative dose intensity",
    "toxicity_rates": "Monitor Grade 3-4 toxicity rates, neutropenic fever, hospitalizations",
    "patient_satisfaction": "Quality of life assessments, symptom management adequacy"
  }
}
